J
John Frew
Researcher at Freeman Hospital
Publications - 13
Citations - 470
John Frew is an academic researcher from Freeman Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications receiving 211 citations.
Papers
More filters
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group.
Stephen Morris,Julia Scarisbrick,John Frew,Clive Irwin,R. J. Grieve,Caroline Humber,Aleksandra Kuciejewska,Sally Bayne,Fiona Child,Mary Wain,Sean Whittaker +10 more
TL;DR: The low-dose TSEB schedule of 12 Gy in 8 fractions over a period of 2 weeks is well tolerated and is an effective option for patients with mycosis fungoides.
Journal ArticleDOI
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
David P. Dearnaley,Clare Griffin,Rebecca Lewis,P. Mayles,Helen Mayles,O. Naismith,V. Harris,Christopher D Scrase,John Staffurth,Isabel Syndikus,Anjali Zarkar,Daniel Ford,Yvonne Rimmer,Gail Horan,Vincent Khoo,John Frew,Ramachandran Venkitaraman,Emma Hall +17 more
TL;DR: PIVOTAL demonstrated that high-dose pelvic lymph node IMRT can be delivered at multiple centers with a modest side effect profile and the impact of P&P IMRT on disease control remains to be established.
Journal ArticleDOI
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Alison Tree,Peter Ostler,H. van der Voet,William C. Cho,Andrew Loblaw,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,John G. Armstrong,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,A. Duffton,Douglas Brand,D. Henderson,Kirsty Morrison,Stephanie Brown,Julia Pugh,Stephanie Burnett,Muneeb Mahmud,Victoria Hinder,O. Naismith,Emma Hall,Nicholas van As +27 more
TL;DR: PACE-B as discussed by the authors , a randomized trial of conventional fractionated or moderately hypofractionated radiotherapy versus Stereotactic Body Radiotherapy (SBRT), was conducted at 35 hospitals in the UK, Ireland, and Canada.
Journal ArticleDOI
A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.
Simon J. Crabb,Syed A. Hussain,E. Soulis,Samantha Hinsley,L. Dempsey,Avril Trevethan,Yee Pei Song,Jim Barber,John Frew,Joanna Gale,Guy Faust,Susannah Brock,Ursula McGovern,Omi Parikh,Deborah Enting,Santhanam Sundar,Gihan Ratnayake,Kathryn Lees,Thomas Powles,Robert Jones +19 more
TL;DR: Investigation of PARP inhibition for mUC is warranted and maintenance rucaparib, following PBC, extended PFS in DRD biomarker selected patients with mUC and is tolerable.